Form 4: Natera Executive Sells Shares Under 10b5-1 Plan

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 2,900 shares of common stock on December 1, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), reported the sale of 2,900 shares of common stock.
• The transactions occurred on December 1, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024.
• The shares were sold in multiple transactions at weighted average prices ranging from $237.2275 to $239.5261 per share.
• Following these transactions, Solomon Moshkevich beneficially owns 109,061 shares of Natera common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported sales are part of a pre-arranged 10b5-1 trading plan, which typically indicates a routine liquidity event rather than a reaction to new company-specific information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance and not necessarily based on new, undisclosed negative information about the company.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the executive's direct equity stake in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Natera's future performance or outlook.

Industry Context

This insider transaction is a routine disclosure and does not provide specific insights into broader industry trends or Natera's competitive position within the clinical diagnostics sector.

Stakeholder Impact

• Shareholders: May view the sale as a routine personal financial planning event due to the 10b5-1 plan, or some may interpret it as a slight reduction in insider confidence, though the latter is less likely given the pre-planned nature.

Key Dates

Recommendation

The filing reports a pre-scheduled sale of shares by an executive under a Rule 10b5-1 plan. Such sales are typically for personal financial planning and do not necessarily reflect a change in the executive's outlook on the company's future performance. While any insider sale can be viewed with caution, the pre-planned nature mitigates immediate concerns. The transaction itself does not provide new fundamental information to warrant a change in investment stance.

Keywords

Natera, NTRA, Insider Trading, Form 4, Stock Sale, Solomon Moshkevich, 10b5-1 Plan, Clinical Diagnostics